Monoclonal Antibodies To Hiv Coreceptors
Award last edited on: 7/18/08

Sponsored Program
Awarding Agency
Total Award Amount
Award Phase
Solicitation Topic Code

Principal Investigator
Monica L Tsang

Company Information

R And D Systems Inc (AKA: Research and Diagnostic Systems, Inc)

614 Mc Kinley Place Ne
Minneapolis, MN 55413
   (612) 379-2956
Location: Multiple
Congr. District: 05
County: Hennepin

Phase I

Contract Number: 1R43AI041299-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
Phase I Amount
(Adapted from applicant's abstract): The long term commercial objective of the proposed research is to make available to the research community a complete set of monoclonal antibodies to all key epitopes of the major HIV-1 coreceptors CCR5 and fusin. The availability of these antibodies is essential for the basic understanding of molecular interactions between these HIV coreceptors/chemokine receptors and their cognate ligands. These antibodies will aid in the discovery of novel therapeutic drugs for AIDS and other inflammatory diseases. They can also be used judiciously for the identification of HIV-1-resistant individuals in the population. Specific aims during phase I will include: the immunization of mice with transfected mouse cells expressing CCR5 or fusin on their surfaces; the primary screening of hybridoma supernatants by whole cell ELISA immunoassays using transfected human 293 cells expressing the receptors; the construction of epitope tagged CCR5 and fusin expression clones for subsequent recombinant membrane protein expression and purification; and the preparation of epitope tagged peptides corresponding to the extracellular domain and three extracellular loops of the receptors. During phase II, the primary clones identified during pase I will be further screened, characterized and epitope mapped using biosensor, flow cytometry and functional assays (Ca mobilization, env-mediated fusion etc).

Thesaurus Terms:
antireceptor antibody, chemokine, cytokine receptor, drug design /synthesis /production, human immunodeficiency virus 1, monoclonal antibody, virus receptor AIDS therapy, active immunization, receptor expression, recombinant protein, virus infection mechanism cell line, enzyme linked immunosorbent assay, epitope mapping, flow cytometry, hybridoma, immunocytochemistry, immunoprecipitation, laboratory mouse, western blottingNational Institute of Allergy and Infectious Diseases (NIAID)

Phase II

Contract Number: 2R44AI041299-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
(last award dollars: 1999)
Phase II Amount

Chemokine receptors/HIV-1 coreceptors are important for understanding viral entry and HIV-1 pathogenesis. However, little is known about their distribution, their structure-function relationships with viral envelope proteins or chemokines, and because there are few tools for studying receptor function. We propose to generate additional panels of monoclonal antibodies to all know HIV-1 coreceptors. These antibodies will be used to study receptor distribution and regulation of expression. They can be used in attempts to block HIV-1 infection of virus cell types in order to determine if a given receptor can function as a coreceptor to enable virus strains to enter specific types of cells. These antibodies can be used for structure-function studies and in competition assays to study how env protein interacts with various coreceptors. Specific high affinity antibodies may also have the potential to be used as therapeutic agents in certain circumstances. We propose a collaborative approach in Phase II that utilizes the strengths of R&D Systems and our academic collaborators to develop additional antibodies with several novel approaches. These antibodies will be characterized in a variety of assays, taking advantage of the large panel of chimeric and mutant receptors developed by, as well as the expertise of our collaborators in studying HIV-1, HIV-1-2 and SIV and their coreceptor interactions. PROPOSED COMMERCIAL APPLICATION: We plan to generate panels of monoclonal antibodies to all of the known chemokine receptors/HIV coreceptors. These antibodies will be made commercially available to researches for studies on: (1) the distribution and regulation of expression of these receptors; (2) blocking HIV infections to determine if given receptors can function as coreceptors for infection of specific cell types by various viral strains; (3) the nature of the interaction between env protein and various coreceptors. Specific humanized, high affinity monoclonal antibodies that block penetration of specific cell types by various HIV strains may have the potential to be used as therapeutic agents under particular circumstances.